JP7211961B2 - 酸性ｐＨでＶＩＳＴＡに結合する抗体 - Google Patents

酸性ｐＨでＶＩＳＴＡに結合する抗体 Download PDF

Info

Publication number
JP7211961B2
JP7211961B2 JP2019549389A JP2019549389A JP7211961B2 JP 7211961 B2 JP7211961 B2 JP 7211961B2 JP 2019549389 A JP2019549389 A JP 2019549389A JP 2019549389 A JP2019549389 A JP 2019549389A JP 7211961 B2 JP7211961 B2 JP 7211961B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
light chain
seq
e100ff
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509756A (ja
JP2020509756A5 (https=
Inventor
ロバート ジェー． ジョンストン，
アルビンド ラジパール，
ポール オー． シェパード，
ルイス ボルヘス，
アンドリュー ランキン，
キース サアドゥン バハジャト，
アラン ジェー． コーマン，
アンディ エックス． トン，
リン ホイ スー，
ジンジャー レイクストロー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020509756A publication Critical patent/JP2020509756A/ja
Publication of JP2020509756A5 publication Critical patent/JP2020509756A5/ja
Priority to JP2023002879A priority Critical patent/JP7573659B2/ja
Application granted granted Critical
Publication of JP7211961B2 publication Critical patent/JP7211961B2/ja
Priority to JP2024179648A priority patent/JP2025023919A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019549389A 2017-03-14 2018-03-13 酸性ｐＨでＶＩＳＴＡに結合する抗体 Active JP7211961B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023002879A JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2024179648A JP2025023919A (ja) 2017-03-14 2024-10-15 酸性ｐＨでＶＩＳＴＡに結合する抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471196P 2017-03-14 2017-03-14
US62/471,196 2017-03-14
US201862636746P 2018-02-28 2018-02-28
US62/636,746 2018-02-28
PCT/US2018/022230 WO2018169993A1 (en) 2017-03-14 2018-03-13 Antibodies binding to vista at acidic ph

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023002879A Division JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体

Publications (3)

Publication Number Publication Date
JP2020509756A JP2020509756A (ja) 2020-04-02
JP2020509756A5 JP2020509756A5 (https=) 2021-04-30
JP7211961B2 true JP7211961B2 (ja) 2023-01-24

Family

ID=63522565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549389A Active JP7211961B2 (ja) 2017-03-14 2018-03-13 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2023002879A Active JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2024179648A Pending JP2025023919A (ja) 2017-03-14 2024-10-15 酸性ｐＨでＶＩＳＴＡに結合する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023002879A Active JP7573659B2 (ja) 2017-03-14 2023-01-12 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP2024179648A Pending JP2025023919A (ja) 2017-03-14 2024-10-15 酸性ｐＨでＶＩＳＴＡに結合する抗体

Country Status (18)

Country Link
US (3) US11603406B2 (https=)
EP (1) EP3595720A4 (https=)
JP (3) JP7211961B2 (https=)
KR (2) KR20240151866A (https=)
CN (2) CN118894937A (https=)
AU (2) AU2018236218B2 (https=)
BR (1) BR112019019108A2 (https=)
CA (1) CA3054067A1 (https=)
CL (2) CL2019002610A1 (https=)
CO (1) CO2019010943A2 (https=)
IL (2) IL269240B1 (https=)
MX (1) MX2024003316A (https=)
MY (1) MY200609A (https=)
PE (2) PE20250933A1 (https=)
SG (1) SG11201907848YA (https=)
TW (2) TWI890190B (https=)
WO (1) WO2018169993A1 (https=)
ZA (1) ZA201905525B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
WO2014159562A1 (en) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
PE20210687A1 (es) * 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
CN112740043A (zh) * 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CA3149719A1 (en) * 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
AU2020403913B2 (en) 2019-12-18 2024-10-10 F. Hoffmann-La Roche Ag Bispecific anti-CCL2 antibodies
US20240132593A1 (en) * 2021-02-18 2024-04-25 Kineta, Inc. Anti-vista antibodies and uses thereof
EP4373848A2 (en) 2021-07-22 2024-05-29 University of Dundee Therapeutic muteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5605821A (en) 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
ES2183851T3 (es) 1990-07-17 2003-04-01 Univ Oklahoma Ligando de gmp-140.
WO1994010309A1 (en) 1992-10-23 1994-05-11 Genetics Institute, Inc. Novel p-selectin ligand protein
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
AU681369B2 (en) 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
WO1995030001A2 (en) 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
KR100523506B1 (en) 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
US5998588A (en) 1995-09-01 1999-12-07 University Of Washington Interactive molecular conjugates
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002508167A (ja) 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
AU5249700A (en) 1999-07-08 2001-01-30 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
WO2001073028A2 (en) 2000-03-24 2001-10-04 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
PT1781682E (pt) 2004-06-24 2013-05-14 Mayo Foundation B7-h5, um polipéptido coestimulante
US8231872B2 (en) 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
US8236304B2 (en) 2005-04-25 2012-08-07 Trustees Of Dartmouth College Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
US20070160601A1 (en) 2005-12-09 2007-07-12 Angela Widom Neutralizing antibodies against primate psgl-1 and uses therefor
US7655778B2 (en) 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
ATE536369T1 (de) 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
JP2010534469A (ja) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ Ｋｄｒ指向性標的化結合物質およびその使用
EP2650017A3 (en) 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
WO2009111507A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
US7833530B2 (en) 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
CN102369296A (zh) 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
MX374075B (es) 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
RU2585489C2 (ru) 2010-04-27 2016-05-27 Рош Гликарт Аг КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
MX349622B (es) * 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
US9587014B2 (en) * 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
JP6181066B2 (ja) 2011-11-28 2017-08-16 ショー，グレイ，ディー． 新規な増強型セレクチンアンタゴニスト
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015097536A2 (en) * 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
EP3094346B1 (en) 2014-01-14 2019-12-11 The Trustees Of Dartmouth College Vista antagonist and methods of use
RU2550262C1 (ru) 2014-02-28 2015-05-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
WO2015187359A1 (en) 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
PT3166636T (pt) 2014-07-08 2021-06-29 Sanford Burnham Med Res Inst Moduladores de psgl-1 e utilizações dos mesmos
JOP20150008B1 (ar) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv أجسام مضادة ل vista وأجزاء منها
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017078839A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
IL260289B (en) 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017137830A1 (en) * 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
WO2018195772A1 (en) 2017-04-25 2018-11-01 Sun Yat-Sen University Pd-1h as target in treatement of asthma
WO2018237287A1 (en) 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
BR112020007755A2 (pt) 2017-10-20 2020-10-20 Pharmabcine Inc. anticorpo anti-vista e uso do mesmo
AU2018360389B2 (en) 2017-11-06 2024-09-19 Aurigene Oncology Limited Conjoint therapies for immunomodulation
EP3755350A4 (en) 2018-02-23 2021-11-03 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER
BR112020019083A2 (pt) * 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
WO2019185163A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Vista antigen-binding molecules
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
CN109878421B (zh) 2019-03-13 2020-11-03 浙江吉利控股集团有限公司 车辆坡道装置及汽车
CN110563843A (zh) 2019-07-25 2019-12-13 钟小泉 一种靶向人vista蛋白的单克隆抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2013134743A1 (en) 2012-03-08 2013-09-12 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal for ImmunoTherapy of Cancer, 2016, Vol.4, No.86, pp.1-7

Also Published As

Publication number Publication date
EP3595720A4 (en) 2021-05-26
JP2025023919A (ja) 2025-02-19
US12195535B2 (en) 2025-01-14
ZA201905525B (en) 2024-12-18
CL2021002769A1 (es) 2022-08-12
TW201843171A (zh) 2018-12-16
IL326895A (en) 2026-04-01
AU2018236218A1 (en) 2019-09-12
TWI890190B (zh) 2025-07-11
KR20190128198A (ko) 2019-11-15
MY200609A (en) 2024-01-05
JP2023061927A (ja) 2023-05-02
IL269240A (en) 2019-11-28
EP3595720A1 (en) 2020-01-22
PE20191708A1 (es) 2019-11-28
US20200055936A1 (en) 2020-02-20
US20240092907A1 (en) 2024-03-21
CN110740749B (zh) 2024-12-10
CN118894937A (zh) 2024-11-05
JP2020509756A (ja) 2020-04-02
JP7573659B2 (ja) 2024-10-25
TWI825010B (zh) 2023-12-11
US20250206822A1 (en) 2025-06-26
CA3054067A1 (en) 2018-09-20
KR20240151866A (ko) 2024-10-18
CO2019010943A2 (es) 2020-01-17
SG11201907848YA (en) 2019-09-27
WO2018169993A1 (en) 2018-09-20
CL2019002610A1 (es) 2019-11-29
MX2024003316A (es) 2024-04-04
AU2025203967A1 (en) 2025-07-03
AU2018236218B2 (en) 2025-03-06
IL269240B1 (en) 2026-04-01
BR112019019108A2 (pt) 2020-04-22
CN110740749A (zh) 2020-01-31
PE20250933A1 (es) 2025-04-02
TW202423986A (zh) 2024-06-16
US11603406B2 (en) 2023-03-14
KR102715540B1 (ko) 2024-10-08

Similar Documents

Publication Publication Date Title
JP7573659B2 (ja) 酸性ｐＨでＶＩＳＴＡに結合する抗体
US20250129166A1 (en) Antibodies Binding to Vista at Acidic pH
JP7700036B2 (ja) 酸性ｐＨでＶＩＳＴＡと結合する抗体
JP7650867B2 (ja) 酸性ｐＨでＶＩＳＴＡと結合する抗体
EA042790B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH
EA046477B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230112

R150 Certificate of patent or registration of utility model

Ref document number: 7211961

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250